𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mutations and polymorphisms of the p21B transcript in breast cancer

✍ Scribed by Stian Knappskog; Ranjan Chrisanthar; Vidar Staalesen; Anne-Lise Børresen-Dale; Inger Torhild Gram; Johan Richard Lillehaug; Per Eystein Lønning

Publisher
John Wiley and Sons
Year
2007
Tongue
French
Weight
70 KB
Volume
121
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

p21^WAF1/CIP1^, transcribed from the CDKN1A locus, plays a key role executing p53‐induced growth arrest. The recent discovery that an alternative transcript, p21B, induces apoptosis, suggests an additional important function of this gene. Here, we report p21 and p21B mutation status in large cohorts of breast cancers and compare distributions of p21B polymorphisms in cancer patients to healthy controls. In 521 breast tumor samples analyzed, only one point mutation affecting the p21B protein was observed. No mutations were found when screening a panel of 20 established cell lines. A novel polymorphism, p21B^G128T^ was identified. Haplotype analysis revealed no association between this variant and the previously identified p21B polymorphism p21B^T35C^ or any of the known p21^WAF1/CIP1^ polymorphisms. As previously reported for p21B^T35C^, distribution of p21B^G128T^ was similar among breast cancer patients and healthy controls (n = 691 and 1,015; incidence 6.1 vs. 4.8%; p = 0.273, respectively). No association between p21B^G128T^ or p21B^T35C^ and response to chemotherapy with an anthracycline‐containing regimen or paclitaxel was recorded. Our findings do not suggest mutations or polymorphisms of p21B to play a major role with respect to either breast cancer risk or sensitivity towards chemotherapy. © 2007 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Polymorphisms in drug metabolism genes,
Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer
✍ Beth O. Van Emburgh; Jennifer J. Hu; Edward A. Levine; Libyadda J. Mosley; L. Do 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

## Abstract Polymorphisms in phase I and phase II enzymes may enhance the occurrence of mutations at critical tumor suppressor genes, such as __p53__, and increase breast cancer risk by either increasing the activation or detoxification of carcinogens and/or endogenous estrogens. We analyzed polymo

P21/WAF1 mutation and drug resistance to
P21/WAF1 mutation and drug resistance to paclitaxel in locally advanced breast cancer
✍ Ranjan Chrisanthar; Stian Knappskog; Vidar Staalesen; Johan Richard Lillehaug; P 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 40 KB

We read with great interest the recent article by Galmarini and colleagues in the journal. 1 The authors reported a point mutation in exon 2 of the p21 gene (WAF1, CIP1, CDKN1A), leading to a premature STOP in codon 127 and paclitaxel resistance in noncancerous epithelial breast cells. The cyclin-de

Mutational analysis of the p73 Gene in h
Mutational analysis of the p73 Gene in human breast cancers
✍ Tomotane Shishikura; Shingo Ichimiya; Toshinori Ozaki; Yoshinori Nimura; Hajime 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 163 KB 👁 2 views

In primary breast cancer, mutations of the p53 tumor suppressor gene lead to loss of growth-suppressive properties and poor outcome. Recently, a p53-related gene, termed p73, has been cloned and its gene product possesses a function similar to p53. p73 has been mapped at chromosome 1p36.3, a region

DNA repair gene polymorphisms and probab
DNA repair gene polymorphisms and probability of p53 mutation in bladder cancer
✍ Mariana C. Stern; Kathleen Conway; Yu Li; Kusum Mistry; Jack A. Taylor 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

We investigated if the presence of single nucleotide polymorphisms (SNPs) in the XRCC1, XRCC3, and XPD genes were associated with the type and frequency of p53 mutations in bladder cancer. Using a hospital-based case-control study we have previously reported risks for the XRCC1 codon 194, XRCC1 codo